checkAd

    DGAP-Adhoc  552  0 Kommentare Epigenomics AG: Blitz F16-83 GmbH to launch takeover offer for Epigenomics AG - Seite 3


    Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon(R), is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.



    For more information, please visit www.epigenomics.com.



    Forward-Looking Statements



    This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.







    Lesen Sie auch


    26-Apr-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de





























    Language: English
    Company: Epigenomics AG
    Geneststraße 5
    10829 Berlin
    Germany
    Phone: +49 30 24345-0
    Fax: +49 30 24345-555
    E-mail: ir@epigenomics.com
    Internet: www.epigenomics.com
    ISIN: DE000A11QW50
    WKN: A11QW5
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange





     
    End of Announcement DGAP News Service




    567465  26-Apr-2017 CET/CEST








    Seite 3 von 3



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Epigenomics AG: Blitz F16-83 GmbH to launch takeover offer for Epigenomics AG - Seite 3 DGAP-Ad-hoc: Epigenomics AG / Key word(s): Takeover Epigenomics AG: Blitz F16-83 GmbH to launch takeover offer for Epigenomics AG 26-Apr-2017 / 03:43 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a …